{"altmetric_id":4900922,"counts":{"readers":{"mendeley":0,"citeulike":0,"connotea":0},"total":{"posts_count":1},"facebook":{"unique_users_count":1,"unique_users":["910560922312087"],"posts_count":1}},"citation":{"authors":["Saki Manabe"],"doi":"10.4236\/jct.2015.615132","first_seen_on":"2015-12-20T14:20:23+00:00","issns":[],"journal":"Journal of Cancer Therapy","last_mentioned_on":1450150144,"links":["http:\/\/www.scirp.org\/Journal\/PaperInformation.aspx?PaperID=61883#.Vm-ItOXO5pE.facebook"],"pdf_url":"http:\/\/www.scirp.org\/journal\/PaperDownload.aspx?paperID=61883","pubdate":"2015-12-11T00:00:00+00:00","publisher":"Scientific Research Publishing","title":"Phase II Study of Carboplatin and Pemetrexed Followed by Gefitinib for Patients with Advanced Non-Small Cell Lung Cancer Harboring Sensitive EGFR Mutation","type":"article"},"altmetric_score":{"score":0.25,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":0.25},"context_for_score":null},"demographics":[],"posts":{"facebook":[{"title":"Phase II Study of Carboplatin and Pemetrexed Followed by Gefitinib for Patients with Advanced...","url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=1109264619108382&id=910560922312087","license":"public","citation_ids":[4900922],"posted_on":"2015-12-15T03:29:04+00:00","summary":"We conducted a phase II study of combination chemotherapy with carboplatin (Cb) and pemetrexed (Pem) followed by gefitinib (Gef) to determine the effects and toxicities in patients with non-small cell lung cancer (NSCLC) harboring sensitive EGFR mutation.","author":{"name":"Scirp  HealthLife","url":"https:\/\/www.facebook.com\/910560922312087","facebook_wall_name":"Scirp  HealthLife","image":"https:\/\/graph.facebook.com\/910560922312087\/picture","id_on_source":"910560922312087"}}]}}